CAS: 190900-21-1; Tert-Butyl 5-Oxo-1,4-Diazepane-1-Carboxylate

相似化合物

34376-54-0 5441-40-7 208245-76-5

上下游产品

CAS号150008-24-5 4-肟-1-B°C-哌啶 | CAS号34376-54-0 2,3,6,7-四氢-(1H)... | CAS号24424-99-5 二碳酸二叔丁酯 | CAS号99822-50-1 1,4-二氮杂环庚-2-酮 | CAS号55186-89-5 1-苄基-1,4-二氮杂环庚-5-酮 | CAS号79099-07-3 1-B°C-4-哌啶酮 | CAS号34376-54-0 2,3,6,7-四氢-(1H)...

4-(羟基亚氨基)哌啶-1-羧酸叔丁酯置于1-丙基磷酸酐体系中,用 四氢呋喃,乙酸乙酯 用作溶剂,以84%的收率获得1-Boc-1,4-二氮杂-5-环庚酮
参考文献:由丙基膦酸酐(t3P®)介导的将酮肟肟化成酰胺,醛肟化成腈的贝克曼重排的有效催化方法
标题:由丙基膦酸酐(t3P®)介导的将酮肟肟化成酰胺,醛肟化成腈的贝克曼重排的有效催化方法
摘要:描述了一种由催化量(15摩尔%)的丙基膦酸酐介导的将酮肟的贝克曼重排成酰胺的有效方法.Aldoximes在室温下与t3P(15 Mol%)反应后,进行了二阶beckmann重排,从而以优异的收率提供了相应的腈.这种环境友好协议的主要优点包括程序简单,尤其是产品隔离容易.
Doi:10.1016/j.Tetlet.2010.12.090

专利信息

专利号:US-8772301-B2
优先权日:2009-12-18
标题 :Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
发明人：HARDY LARRY WENDELL; HEFFERNAN MICHELE L R; WU FRANK XINHE; SPEAR KERRY L; SARASWAT LAKSHMI D
权利人:HARDY LARRY WENDELL; HEFFERNAN MICHELE L R; WU FRANK XINHE; SPEAR KERRY L; SARASWAT LAKSHMI D; SUNOVION PHARMACEUTICALS INC
摘要:Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

专利号:US-8404670-B2
优先权日:2009-02-11
标题:Histamine H3 inverse agonists and antagonists and methods of use thereof
发明人：CHYTIL MILAN; ENGEL SHARON R; FANG QUN KEVIN; SPEAR KERRY L
权利人:CHYTIL MILAN; ENGEL SHARON R; FANG QUN KEVIN; SPEAR KERRY L; SUNOVION PHARMACEUTICALS INC
摘要:Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.